Join us to learn the essentials of Food and Drug Administration (FDA) law and regulation and the role of patient organizations.

For this one-and-a-half-day program, FDLI brings together law, industry, and FDA experts with deep advocacy experience to equip patient organizations with an understanding of the legal tools and strategies available for interacting with the agency. Case studies will illustrate the opportunities for engagement and legal challenges facing patient organizations.

Agenda Highlights Include:

  • New Drug Development & Clinical Trials Regulation
  • Submission of Marketing Applications & the FDA Approval Process
  • Expanded Access
  • Interacting with Drug Development Enterprise & FDA

A special thanks to:

Program Partners:

Apply Now

FDLI, in conjunction with our partners and sponsors, offer this program for patient organizations and related non-profits.

The course agenda was specifically designed to equip patient organizations with an understanding of the legal tools and strategies available for interacting with the FDA throughout the drug development process.

Patient Organizations and
Related Non-Profits

$49
  • Deadline to Apply: Monday, October 2

Applications indicate interest and do not guarantee course attendance. Applicants will be accepted on a rolling basis.

View our full introductory course offerings.

If you are interested in this program, but unable to attend, please let us know. We hope to continue to offer patient organization specific programs.

Agenda

subject to change

Tuesday, November 7

10:30 AM
Registration

11:00 – 11:05 AM
Welcome and Announcements

11:05 – 11:50 AM
Introduction to FDA

David L. Chesney, Principal and General Manager, DL Chesney Consulting, LLC

  • The U.S. Drug Regulatory Process
  • Congressional Oversight

11:50 – 12:30 PM
Beyond FDA: FDA’s Relationship with Other Federal Agencies

David Horowitz, Partner, Hogan Lovells

12:30 – 1:00 PM
Lunch

1:00 – 1:45 PM
Hatch-Waxman and Other Statutory Incentives

David Ceryak, Senior Director, Assistant General Counsel, Regulatory Legal Team, Eli Lilly and Company

  • Patent Term Restoration/Extension
  • Five- and Three-Year Exclusivity
  • 180-Day Exclusivity
  • Pediatric Exclusivity
  • Orphan Drugs
  • Priority Review Vouchers (tropical disease, rare pediatric disease, and medical countermeasures) (PRVs)

1:45 – 2:45 PM
Investigational New Drug Application (IND) and New Drug Development

Jason Saspin, Counsel, Faegre Baker Daniels LLP              

  • What is a “Drug”?
  • What is a “New Drug”?
  • Other-drug like products
  • Who decides whether a product is a “New Drug”?
  • The Investigational New Drug (IND) Process
  • IND Application

2:45 – 3:00 PM
Refreshment Break

3:00 – 4:00 PM
Conduct of Clinical Trials and Human Subjects Protections

Lance Shea, Partner, Baker & Hostetler LLP

  • Clinical Testing/Investigation and “Good Clinical Practice” (GCP)
  • Clinical Trials Registration and Results Reporting (clinicaltrials.gov)
  • Human Subjects Research Protection
  • Bioresearch Monitoring (BIMO)

4:00 – 5:30 PM
Submission of Marketing Applications & the FDA Approval Process

James Valentine, Associate, Hyman, Phelps & McNamara, PC

  • Submission & filing of NDAs/BLAs
  • Approval Standards
  • The Review Process
  • Expedited Review
  • Unapproved Uses of Drugs

5:30 PM
Reception

Wednesday, November 8

9:00 – 10:00 AM
Expanded Access to Investigational Therapies

Richard Klein, Former Director, Patient Liaison Program, FDA

  • Expanded Access
  • State Right-to-Try statutes

10:00 – 11:00 AM
Post-Approval Obligations of Drug Companies

Geoffrey M. Levitt, Senior Vice President and Associate General Counsel, Regulatory, Environmental, and Global Supply, Pfizer Inc.

  • Post-Approval (“Phase IV”) Investigations
  • Withdrawal of Approval
  • Annual Reports
  • Adverse Drug Experience (ADE) Reports
  • Post-Approval Changes and Supplemental NDAs (sNDAs) and ANDA’s
  • Grounds for Withdrawal of Approval
  • Sale/Transfer of NDAs/ANDA’s
  • Post-Approval Safety Issues

11:00 – 11:15 AM
Refreshment Break

11:15 –12:15 PM
Stakeholder Interactions in the Drug Development Community
                                                                          

  • Sponsor-patient group engagement
  • Other stakeholders

12:15  – 1:15 PM
Luncheon

1:15 – 2:15 PM
Engaging with FDA: Opportunities and Boundaries

Kim McCleary, Managing Director, FasterCures

  • FDA’s Patient Engagement Offices
  • FDA’s Patient Engagement Programs
  • Participating in FDA Policymaking

2:15 – 3:00 PM
Question & Answer Panel            

3:00 PM
Adjournment

Planning Commitee

Marc Boutin, Chief Executive Officer, National Health Council
Maureen Japha, formerly Director, Regulatory Policy, FasterCures
Annie Kennedy, Senior Vice President, Legislation & Public Policy, Parent Project Muscular Dystrophy
Debra Lappin, Principal, Faegre Baker Daniels
Katherine Maynard, Communications, Peterson Wilmarth and Robertson LLP
Diane Robertson, Attorney, Peterson Wilmarth and Robertson LLP
James Valentine, Associate, Hyman, Phelps & McNamara, P.C.

Location

Milken Institute School of Public Health
At the George Washington University
950 New Hampshire Ave, NW
Washington, DC 20052